Therapeutic Advances in Medical Oncology
@tamedoncol.bsky.social
A SAGE Publishing Gold #openaccess journal | Publishing innovative clinically focused articles on the medical treatment of cancer| PubMed Indexed | IF: 4.3
Network meta-analysis of 11 RCTs: EV+pembrolizumab ranks highest for OS, PFS & ORR in la/mUC. Safety acceptable vs chemo. Details buff.ly/Wsqr2nQ
#CancerResearch #BladderCancer
#CancerResearch #BladderCancer
November 23, 2025 at 8:15 AM
Network meta-analysis of 11 RCTs: EV+pembrolizumab ranks highest for OS, PFS & ORR in la/mUC. Safety acceptable vs chemo. Details buff.ly/Wsqr2nQ
#CancerResearch #BladderCancer
#CancerResearch #BladderCancer
Many breast cancer survivors face diminished quality of life due to estrogen deprivation.
This review provides updated guidance on vulvovaginal health, safe treatments, and strategies to support endocrine therapy adherence. Full article 👉 buff.ly/RmCbexo #CancerResearch #BreastCancer #Survivorship
This review provides updated guidance on vulvovaginal health, safe treatments, and strategies to support endocrine therapy adherence. Full article 👉 buff.ly/RmCbexo #CancerResearch #BreastCancer #Survivorship
November 20, 2025 at 8:15 AM
Many breast cancer survivors face diminished quality of life due to estrogen deprivation.
This review provides updated guidance on vulvovaginal health, safe treatments, and strategies to support endocrine therapy adherence. Full article 👉 buff.ly/RmCbexo #CancerResearch #BreastCancer #Survivorship
This review provides updated guidance on vulvovaginal health, safe treatments, and strategies to support endocrine therapy adherence. Full article 👉 buff.ly/RmCbexo #CancerResearch #BreastCancer #Survivorship
We’re proud to see our Associate Editor, Prof. Nadia Harbeck, contributing to the upcoming #ESMOYOC YO4YO HowTo session on career crossroads in oncology. Don’t miss it! 📅 25 Nov, 15:00 CET. #YoungOncologists
Get ready for the next YO4YO HowTo Virtual session with Ana Tecic Vuger, Nadia Harbeck and Kevin Punie MD #YoungOncologists #ESMOYOC
📌 Career Crossroads in #Oncology: Clinical, #research, and #leadership journeys
📅 25 November 2025
🕒 15:00–16:00 CET
🔗 https://ow.ly/R7MJ50XpRy1
📌 Career Crossroads in #Oncology: Clinical, #research, and #leadership journeys
📅 25 November 2025
🕒 15:00–16:00 CET
🔗 https://ow.ly/R7MJ50XpRy1
November 17, 2025 at 8:44 AM
We’re proud to see our Associate Editor, Prof. Nadia Harbeck, contributing to the upcoming #ESMOYOC YO4YO HowTo session on career crossroads in oncology. Don’t miss it! 📅 25 Nov, 15:00 CET. #YoungOncologists
🔬 CDK4/6 inhibitors have transformed HR+ MBC care - but resistance is a growing challenge.
This review explores the molecular drivers and emerging strategies to counteract them. Full article 👉 buff.ly/1YracNB #CancerResearch #Oncology
This review explores the molecular drivers and emerging strategies to counteract them. Full article 👉 buff.ly/1YracNB #CancerResearch #Oncology
November 17, 2025 at 8:15 AM
🔬 CDK4/6 inhibitors have transformed HR+ MBC care - but resistance is a growing challenge.
This review explores the molecular drivers and emerging strategies to counteract them. Full article 👉 buff.ly/1YracNB #CancerResearch #Oncology
This review explores the molecular drivers and emerging strategies to counteract them. Full article 👉 buff.ly/1YracNB #CancerResearch #Oncology
Reposted by Therapeutic Advances in Medical Oncology
Kicking off #SIBCS2025 in Shanghai! Proud to represent Sage Publishing as Editor of Therapeutic Advances in Medical Oncology and Co-Editor of Clinical Medicine Insights: Oncology + Rare Tumors.
Come say hi at booth #29! 🧬📚 #BreastCancer #Oncology #MedicalResearch
Come say hi at booth #29! 🧬📚 #BreastCancer #Oncology #MedicalResearch
November 14, 2025 at 2:36 AM
Kicking off #SIBCS2025 in Shanghai! Proud to represent Sage Publishing as Editor of Therapeutic Advances in Medical Oncology and Co-Editor of Clinical Medicine Insights: Oncology + Rare Tumors.
Come say hi at booth #29! 🧬📚 #BreastCancer #Oncology #MedicalResearch
Come say hi at booth #29! 🧬📚 #BreastCancer #Oncology #MedicalResearch
🔬 New insights into HER2-low TNBC: • 47.7% of Asian TNBC patients classified as HER2-low • Distinct genomic profile (↓ BRCA1, ↑ PIK3CA) • No difference in survival outcomes vs HER2-zero
Full study 👉 buff.ly/kXKMwn8 #BreastCancer #HER2 #CancerResearch
Full study 👉 buff.ly/kXKMwn8 #BreastCancer #HER2 #CancerResearch
November 13, 2025 at 8:15 AM
🔬 New insights into HER2-low TNBC: • 47.7% of Asian TNBC patients classified as HER2-low • Distinct genomic profile (↓ BRCA1, ↑ PIK3CA) • No difference in survival outcomes vs HER2-zero
Full study 👉 buff.ly/kXKMwn8 #BreastCancer #HER2 #CancerResearch
Full study 👉 buff.ly/kXKMwn8 #BreastCancer #HER2 #CancerResearch
Could the clock be a treatment factor? This retrospective study of 248 patients with mGC found better survival outcomes when nivolumab was infused before mid-afternoon.
Authors suggest infusion timing should be considered in daily practice. Details here: buff.ly/k54we7o
Authors suggest infusion timing should be considered in daily practice. Details here: buff.ly/k54we7o
November 10, 2025 at 9:21 AM
Could the clock be a treatment factor? This retrospective study of 248 patients with mGC found better survival outcomes when nivolumab was infused before mid-afternoon.
Authors suggest infusion timing should be considered in daily practice. Details here: buff.ly/k54we7o
Authors suggest infusion timing should be considered in daily practice. Details here: buff.ly/k54we7o
🧬 Immunotherapy has transformed cancer care-but #prostatecancer remains resistant.
This review explores why traditional approaches fall short and highlights emerging strategies like: Checkpoint inhibitors; T-cell engagers; CAR-T cells
buff.ly/OV5DpZ2
#ProstateCancer #Immunotherapy #Oncology #CAR_T
This review explores why traditional approaches fall short and highlights emerging strategies like: Checkpoint inhibitors; T-cell engagers; CAR-T cells
buff.ly/OV5DpZ2
#ProstateCancer #Immunotherapy #Oncology #CAR_T
Sage Journals: Discover world-class research
Subscription and open access journals from Sage, the world's leading independent academic publisher.
journals.sagepub.com
November 7, 2025 at 8:15 AM
🧬 Immunotherapy has transformed cancer care-but #prostatecancer remains resistant.
This review explores why traditional approaches fall short and highlights emerging strategies like: Checkpoint inhibitors; T-cell engagers; CAR-T cells
buff.ly/OV5DpZ2
#ProstateCancer #Immunotherapy #Oncology #CAR_T
This review explores why traditional approaches fall short and highlights emerging strategies like: Checkpoint inhibitors; T-cell engagers; CAR-T cells
buff.ly/OV5DpZ2
#ProstateCancer #Immunotherapy #Oncology #CAR_T
🏠Can indoor radon affect lung cancer mutations? The RADON EUROPE study shows a link between high radon levels (>400 Bq/m³) and ALK rearrangements in NSCLC across 21 European countries.📍 This emphasizes the need for studying environmental impacts on cancer genomics. buff.ly/C3ktYC5 #LungCancer #NSCLC
Sage Journals: Discover world-class research
Subscription and open access journals from Sage, the world's leading independent academic publisher.
journals.sagepub.com
November 5, 2025 at 8:15 AM
🏠Can indoor radon affect lung cancer mutations? The RADON EUROPE study shows a link between high radon levels (>400 Bq/m³) and ALK rearrangements in NSCLC across 21 European countries.📍 This emphasizes the need for studying environmental impacts on cancer genomics. buff.ly/C3ktYC5 #LungCancer #NSCLC
📢 Study on advanced #PancreaticCancer treatment reveals key survival factors: Only 8.3% of 204 patients lived beyond 2 years. ✅ Longer survival linked to good physical function (PS 0), low CRP & CA 19-9, high albumin, and peritoneal metastasis without fluid buildup.
Sage Journals: Discover world-class research
Subscription and open access journals from Sage, the world's leading independent academic publisher.
journals.sagepub.com
November 3, 2025 at 8:15 AM
📢 Study on advanced #PancreaticCancer treatment reveals key survival factors: Only 8.3% of 204 patients lived beyond 2 years. ✅ Longer survival linked to good physical function (PS 0), low CRP & CA 19-9, high albumin, and peritoneal metastasis without fluid buildup.
📢 Call for Papers!
Submit to our special issue: “Geriatric Oncology: Advancing Cancer Care in an Aging World” buff.ly/ASkDwOt
🗓️ Join the conversation on cancer care for older adults.
#GeriatricOncology #CancerResearch #Oncology #CallForPapers #MedicalPublishing
Submit to our special issue: “Geriatric Oncology: Advancing Cancer Care in an Aging World” buff.ly/ASkDwOt
🗓️ Join the conversation on cancer care for older adults.
#GeriatricOncology #CancerResearch #Oncology #CallForPapers #MedicalPublishing
November 1, 2025 at 7:15 AM
📢 Call for Papers!
Submit to our special issue: “Geriatric Oncology: Advancing Cancer Care in an Aging World” buff.ly/ASkDwOt
🗓️ Join the conversation on cancer care for older adults.
#GeriatricOncology #CancerResearch #Oncology #CallForPapers #MedicalPublishing
Submit to our special issue: “Geriatric Oncology: Advancing Cancer Care in an Aging World” buff.ly/ASkDwOt
🗓️ Join the conversation on cancer care for older adults.
#GeriatricOncology #CancerResearch #Oncology #CallForPapers #MedicalPublishing
Adding anti-angiogenesis therapy to PD-1/PD-L1 + chemo improves PFS and ORR in ES-SCLC, especially in patients under 65. No OS benefit overall. Safety comparable.
🔗 buff.ly/tMshYDZ
#LungCancer #CheckpointInhibitors #MetaAnalysis
🔗 buff.ly/tMshYDZ
#LungCancer #CheckpointInhibitors #MetaAnalysis
Efficacy and safety of first-line PD-1/PD-L1 inhibitors combined with or without anti-angiogenesis therapy for extensive-stage small-cell lung cancer: a network meta-analysis - Linjing Zhou, Yuwei Li, Le Wang, Kaiyan Chen, Shichao Zhou, Yunfei Chen, Jing Sun, Yunfeng Tong, Yun Fan, 2025
Background: Immune checkpoint inhibitors (ICIs) combined with chemotherapy, with or without angiogenesis inhibitors, have been investigated as the first-line tr...
doi.org
October 31, 2025 at 7:15 AM
Adding anti-angiogenesis therapy to PD-1/PD-L1 + chemo improves PFS and ORR in ES-SCLC, especially in patients under 65. No OS benefit overall. Safety comparable.
🔗 buff.ly/tMshYDZ
#LungCancer #CheckpointInhibitors #MetaAnalysis
🔗 buff.ly/tMshYDZ
#LungCancer #CheckpointInhibitors #MetaAnalysis
PD-1/PD-L1 inhibitors show promise in HBV-related hepatocellular carcinoma. Patients with low HBV DNA and early qHBsAg response had longer survival. Viral biomarkers could shape future immunotherapy strategies. buff.ly/ciwROOE
#LiverCancer #HBV #CheckpointInhibitors
#LiverCancer #HBV #CheckpointInhibitors
Relationship between HBsAg/HBV DNA and prognosis in patients with HBV-related hepatocellular carcinoma treated with PD-1/PD-L1 inhibitors - Qiuying Qin, Yuanyuan Zheng, Yiran Wang, Fei Zhou, Dong Li, Linlin Jin, Mujia Zhu, Yabing Guo, Rong Fan, Jinlin Hou, Xiaoyong Zhang, Hongyan Liu, 2025
Objectives: Blocking the programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) axis could reverse the immune tolerance in the liver microenviron...
journals.sagepub.com
October 29, 2025 at 7:15 AM
PD-1/PD-L1 inhibitors show promise in HBV-related hepatocellular carcinoma. Patients with low HBV DNA and early qHBsAg response had longer survival. Viral biomarkers could shape future immunotherapy strategies. buff.ly/ciwROOE
#LiverCancer #HBV #CheckpointInhibitors
#LiverCancer #HBV #CheckpointInhibitors
Pregnancy after BC is not only possible - it’s often safe. But young survivors need tailored, multidisciplinary support to navigate fertility, treatment, and long-term health. More research is needed on novel agents like CDK4/6 and PARP inhibitors. buff.ly/l10yF3b #OncoFertility #BreastCancer
Pregnancy after breast cancer: latest evidence and practical considerations - Nadia Mordenfeld Kozlovsky, Ann H. Partridge, Tal Sella, 2025
Advancements in breast cancer care have significantly improved survival rates in women of all ages; however, young survivors face unique challenges related to f...
journals.sagepub.com
October 27, 2025 at 7:15 AM
Pregnancy after BC is not only possible - it’s often safe. But young survivors need tailored, multidisciplinary support to navigate fertility, treatment, and long-term health. More research is needed on novel agents like CDK4/6 and PARP inhibitors. buff.ly/l10yF3b #OncoFertility #BreastCancer
🧠 New real-world data on HER2-positive MIBC suggests limited benefit from adjuvant chemo or targeted therapy.
With a 5-year DFS of 95.1%, this @tamedoncol.bsky.social study raises important questions about treatment necessity
🔗 buff.ly/HBeagpd
#BreastCancer #HER2 #OncologyResearch
With a 5-year DFS of 95.1%, this @tamedoncol.bsky.social study raises important questions about treatment necessity
🔗 buff.ly/HBeagpd
#BreastCancer #HER2 #OncologyResearch
Sage Journals: Discover world-class research
Subscription and open access journals from Sage, the world's leading independent academic publisher.
journals.sagepub.com
October 24, 2025 at 7:15 AM
🧠 New real-world data on HER2-positive MIBC suggests limited benefit from adjuvant chemo or targeted therapy.
With a 5-year DFS of 95.1%, this @tamedoncol.bsky.social study raises important questions about treatment necessity
🔗 buff.ly/HBeagpd
#BreastCancer #HER2 #OncologyResearch
With a 5-year DFS of 95.1%, this @tamedoncol.bsky.social study raises important questions about treatment necessity
🔗 buff.ly/HBeagpd
#BreastCancer #HER2 #OncologyResearch
Precision matters.
A new @tamedoncol.bsky.social review dives into the evolving landscape of non-clear cell RCC, emphasizing molecular profiling, novel targets, and the 2022 WHO reclassification.
Read more: buff.ly/5jyCunC
#RenalCellCarcinoma #nccRCC #TargetedTherapy
A new @tamedoncol.bsky.social review dives into the evolving landscape of non-clear cell RCC, emphasizing molecular profiling, novel targets, and the 2022 WHO reclassification.
Read more: buff.ly/5jyCunC
#RenalCellCarcinoma #nccRCC #TargetedTherapy
Sage Journals: Discover world-class research
Subscription and open access journals from Sage, the world's leading independent academic publisher.
buff.ly
October 22, 2025 at 7:15 AM
Precision matters.
A new @tamedoncol.bsky.social review dives into the evolving landscape of non-clear cell RCC, emphasizing molecular profiling, novel targets, and the 2022 WHO reclassification.
Read more: buff.ly/5jyCunC
#RenalCellCarcinoma #nccRCC #TargetedTherapy
A new @tamedoncol.bsky.social review dives into the evolving landscape of non-clear cell RCC, emphasizing molecular profiling, novel targets, and the 2022 WHO reclassification.
Read more: buff.ly/5jyCunC
#RenalCellCarcinoma #nccRCC #TargetedTherapy
🚀 The future of #GastricCancer therapy may lie beyond traditional oncogenic targets.
Explore how Claudin18.2, Nectin-4, and Caprin-1 are opening new doors for precision oncology in this @tamedoncol.bsky.social review.
🔗 journals.sagepub.com/doi/full/10....
#OncologyResearch #ESMO25 #CancerTherapy
Explore how Claudin18.2, Nectin-4, and Caprin-1 are opening new doors for precision oncology in this @tamedoncol.bsky.social review.
🔗 journals.sagepub.com/doi/full/10....
#OncologyResearch #ESMO25 #CancerTherapy
Emerging evidence of targeting non-oncogenic drivers for gastric cancer: Claudin18.2 and beyond - Kazumasa Yamamoto, Izuma Nakayama, Kohei Shitara, 2025
Human epidermal growth factor receptor 2 was the first successful molecular target in treating gastric cancer, marking a significant milestone for targeted ther...
journals.sagepub.com
October 20, 2025 at 7:15 AM
🚀 The future of #GastricCancer therapy may lie beyond traditional oncogenic targets.
Explore how Claudin18.2, Nectin-4, and Caprin-1 are opening new doors for precision oncology in this @tamedoncol.bsky.social review.
🔗 journals.sagepub.com/doi/full/10....
#OncologyResearch #ESMO25 #CancerTherapy
Explore how Claudin18.2, Nectin-4, and Caprin-1 are opening new doors for precision oncology in this @tamedoncol.bsky.social review.
🔗 journals.sagepub.com/doi/full/10....
#OncologyResearch #ESMO25 #CancerTherapy
🎉 Honoring excellence in oncology!
Huge congratulations to our Associate Editor Dr. Natasha Leighl on receiving the #ESMO25 Women for Oncology Award.
A true leader in advancing cancer care and inspiring the next generation of researchers.
#WomenInSTEM #OncologyLeadership #lungcancer
Huge congratulations to our Associate Editor Dr. Natasha Leighl on receiving the #ESMO25 Women for Oncology Award.
A true leader in advancing cancer care and inspiring the next generation of researchers.
#WomenInSTEM #OncologyLeadership #lungcancer
Natasha Leighl, recipient of the 2025 ESMO Women for Oncology Award, will present her Award lecture at the #ESMO25 Opening Session. She will discuss key contributions to #LungCancer research & the role of liquid biopsy in #CancerDiagnostics.
📅 Opening Session https://ow.ly/BwMO50XavIS
📅 Opening Session https://ow.ly/BwMO50XavIS
October 17, 2025 at 5:10 AM
🎉 Honoring excellence in oncology!
Huge congratulations to our Associate Editor Dr. Natasha Leighl on receiving the #ESMO25 Women for Oncology Award.
A true leader in advancing cancer care and inspiring the next generation of researchers.
#WomenInSTEM #OncologyLeadership #lungcancer
Huge congratulations to our Associate Editor Dr. Natasha Leighl on receiving the #ESMO25 Women for Oncology Award.
A true leader in advancing cancer care and inspiring the next generation of researchers.
#WomenInSTEM #OncologyLeadership #lungcancer
In non-metastatic HER2− #BreastCancer, NCDB data (2018) showed higher pCR rates with neoadjuvant chemo in HR-Low vs HR-High groups. HR-Low tumors had higher grade/stage and lower endocrine therapy use, underscoring need for clearer treatment guidance.
🔗 journals.sagepub.com/doi/epdf/10....
🔗 journals.sagepub.com/doi/epdf/10....
October 10, 2025 at 3:59 PM
In non-metastatic HER2− #BreastCancer, NCDB data (2018) showed higher pCR rates with neoadjuvant chemo in HR-Low vs HR-High groups. HR-Low tumors had higher grade/stage and lower endocrine therapy use, underscoring need for clearer treatment guidance.
🔗 journals.sagepub.com/doi/epdf/10....
🔗 journals.sagepub.com/doi/epdf/10....
In HR+ advanced #BreastCancer progressing after CDK4/6 inhibitors, network meta-analysis (19 RCTs; n=6621) found CDK4/6i + fulvestrant most effective for PFS, especially in visceral metastases or ESR1 mutations; Bcl-2i + Ful and SERDs also showed benefit
journals.sagepub.com/doi/epdf/10....
journals.sagepub.com/doi/epdf/10....
October 10, 2025 at 3:57 PM
In HR+ advanced #BreastCancer progressing after CDK4/6 inhibitors, network meta-analysis (19 RCTs; n=6621) found CDK4/6i + fulvestrant most effective for PFS, especially in visceral metastases or ESR1 mutations; Bcl-2i + Ful and SERDs also showed benefit
journals.sagepub.com/doi/epdf/10....
journals.sagepub.com/doi/epdf/10....
In HER2+ salivary duct carcinoma, trastuzumab-deruxtecan (T-Dxd) achieved 13 months of disease control in a multitreated 44-year-old patient, supporting further study of anti-HER2 therapy in rare salivary tumors.
🔗 journals.sagepub.com/doi/epdf/10....
#HER2 #SalivaryCancer #Oncology
🔗 journals.sagepub.com/doi/epdf/10....
#HER2 #SalivaryCancer #Oncology
October 10, 2025 at 3:54 PM
In HER2+ salivary duct carcinoma, trastuzumab-deruxtecan (T-Dxd) achieved 13 months of disease control in a multitreated 44-year-old patient, supporting further study of anti-HER2 therapy in rare salivary tumors.
🔗 journals.sagepub.com/doi/epdf/10....
#HER2 #SalivaryCancer #Oncology
🔗 journals.sagepub.com/doi/epdf/10....
#HER2 #SalivaryCancer #Oncology
In HER2-mutated non-small-cell lung cancer, combination regimens achieved markedly better outcomes than single-agent approaches.
Median PFS: 7.8 vs 5.3 mo; best results seen with chemo + immunotherapy + anti-angiogenic therapy.
🔗 journals.sagepub.com/doi/epdf/10....
Median PFS: 7.8 vs 5.3 mo; best results seen with chemo + immunotherapy + anti-angiogenic therapy.
🔗 journals.sagepub.com/doi/epdf/10....
October 10, 2025 at 3:51 PM
In HER2-mutated non-small-cell lung cancer, combination regimens achieved markedly better outcomes than single-agent approaches.
Median PFS: 7.8 vs 5.3 mo; best results seen with chemo + immunotherapy + anti-angiogenic therapy.
🔗 journals.sagepub.com/doi/epdf/10....
Median PFS: 7.8 vs 5.3 mo; best results seen with chemo + immunotherapy + anti-angiogenic therapy.
🔗 journals.sagepub.com/doi/epdf/10....
In patients with metastatic #gastriccancer, earlier nivolumab monotherapy infusions (before 14:00) were associated with significantly longer PFS and OS (7.6 vs 3.9 mo). Authors suggest infusion timing may influence outcomes in #Immunotherapy practice.
🔗 journals.sagepub.com/doi/epdf/10....
🔗 journals.sagepub.com/doi/epdf/10....
October 10, 2025 at 3:48 PM
In patients with metastatic #gastriccancer, earlier nivolumab monotherapy infusions (before 14:00) were associated with significantly longer PFS and OS (7.6 vs 3.9 mo). Authors suggest infusion timing may influence outcomes in #Immunotherapy practice.
🔗 journals.sagepub.com/doi/epdf/10....
🔗 journals.sagepub.com/doi/epdf/10....
Reposted by Therapeutic Advances in Medical Oncology
🚨 Call for Papers – Special Collection! @tamedoncol.bsky.social seeks submissions on: De-escalation of Treatment in Gynecologic Cancers. 🗓️ Submit by March 18, 2026 📥 Submit:
buff.ly
October 10, 2025 at 7:15 AM
🚨 Call for Papers – Special Collection! @tamedoncol.bsky.social seeks submissions on: De-escalation of Treatment in Gynecologic Cancers. 🗓️ Submit by March 18, 2026 📥 Submit:
Ontario study of OHIP data (2015–2022): female cancer diagnostic billing dropped in 2020 (cervical −50.7/100k, breast −13.9/100k) but rebounded sharply in 2021–22, with net excesses across all cancer types. COVID-19 disruptions drove delayed diagnoses.
journals.sagepub.com/doi/epdf/10....
journals.sagepub.com/doi/epdf/10....
October 3, 2025 at 2:53 PM
Ontario study of OHIP data (2015–2022): female cancer diagnostic billing dropped in 2020 (cervical −50.7/100k, breast −13.9/100k) but rebounded sharply in 2021–22, with net excesses across all cancer types. COVID-19 disruptions drove delayed diagnoses.
journals.sagepub.com/doi/epdf/10....
journals.sagepub.com/doi/epdf/10....